PlattNera(01949.HK)公开发售超购约13.67倍预期7月16日上市
格隆汇7月15日丨Platt Nera(01949.HK)公布,发售1亿股,其中配售9000万股,公开发售1000万股;发售价 每股1.25港元;每手2,000股;预期7月16日上市。
公告显示,公开发售获适度超额认购,相当于公开发售项下初步可供认购公开发售股份总数的约13.67倍。
配售项下初步提呈发售的配售股份已获适度超额认购,相当于配售项下初步可供认购配售股份总数约1.71倍。
公告称,所得款项净额估计约为9240万港元。其中,约83.2%用于为集团项目提供资金;约12.7%用于偿还集团现有借贷;约4.1%用于营运资金及其他一般企业用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.